论文部分内容阅读
目的观察重组人白细胞介素11(IL-11)对恶性肿瘤放化疗后引起血小板减少的临床疗效及毒副反应。方法对49例放化疗后伴血小板减少的恶性肿瘤患者分为实验组23例、对照组26例。治疗组在放化疗结束24h后给予按50μg.kg-1.d-1剂量给予IL-11 ih,连续应用至血小板数≥100×109/L。对照组放化疗后不给予IL-11治疗。结果治疗组血小板恢复至≥100×109/L的平均时间为6.3d,明显短于对照组9.3d(P<0.05)。治疗组中不良反应为:发热、肌肉关节疼痛、乏力、头痛、房颤及转氨酶轻度升高。结论应用IL-11可治疗恶性肿瘤放化疗后引起的血小板减少,不良反应可耐受。
Objective To observe the clinical efficacy and toxicity of recombinant human interleukin-11 (IL-11) on thrombocytopenia induced by radiotherapy and chemotherapy in malignant tumor. Methods Forty-nine patients with malignant tumor after thrombocytopenia were divided into experimental group (n = 23) and control group (n = 26). The treatment group was given IL-11 ih 50μg.kg-1.d-1 dose 24 hours after the end of radiotherapy and chemotherapy, continuous application to platelet count ≥100 × 109 / L. The control group did not receive IL-11 after radiotherapy and chemotherapy. Results The mean time to platelet recovery to ≥100 × 109 / L in treatment group was 6.3 days, which was significantly shorter than that in control group (P <0.05). Adverse reactions in the treatment group were fever, muscle and joint pain, weakness, headache, mild increase in atrial fibrillation and transaminase. Conclusions The application of IL-11 can treat thrombocytopenia caused by radiotherapy and chemotherapy in malignant tumors, and the adverse reactions can be tolerated.